Viking Therapeutics announces two VK2735 poster presentations at ObesityWeek
VKTX•Viking Therapeutics will present two VK2735 posters at ObesityWeek, Nov. 14-17, 2026, in Washington, D.C. The presentations cover baseline characteristics in the Phase 3 VANQUISH-2 study and obesity severity and cardiometabolic parameters in the Phase 2 VENTURE study.
1. Poster presentations
Viking Therapeutics will present two VK2735 posters at ObesityWeek, Nov. 14-17, 2026, in Washington, D.C. A Nov. 14 presentation covers baseline characteristics in adults with overweight and type 2 diabetes in the Phase 3 VANQUISH-2 study. A Nov. 15 presentation examines subcutaneous VK2735’s impact on obesity severity and cardiometabolic parameters in the Phase 2 VENTURE study.
